{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:47:07Z","timestamp":1775753227253,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BY-COVID"},{"name":"Horizon Europe funded project from the European Union","award":["HORIZON-INFRA-2021-EMERGENCY-01"],"award-info":[{"award-number":["HORIZON-INFRA-2021-EMERGENCY-01"]}]},{"name":"Horizon Europe funded project from the European Union","award":["101046203"],"award-info":[{"award-number":["101046203"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To assess the impact of large-scale severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination campaigns in real-world settings across regions, we performed a reproducible cross-border comparison of the real-world effectiveness of primary vaccination in preventing SARS-CoV-2 infections across three sites: Aragon (Spain), Brussels and Wallonia (Belgium), and Finland. This observational study emulated a target trial by daily matching primary vaccinated individuals 1:1 to un- or partially vaccinated individuals using propensity scores estimated on a set of relevant confounders from January to September 2021. Matched individuals were followed up until a SARS-CoV-2 infection was contracted or a censoring event occurred. Vaccine effectiveness in preventing infections was estimated by the difference in restricted mean survival time (RMST). Primary vaccination extended the average free-of-infection time by 35.9 [95% confidence interval (CI) (34.9\u201337.0)], 59.6 [95% CI (59.3\u201360.0)], and 1.6 [95% CI (1.1\u20132.0)] days over 365\u2009days in the population cohort of Aragon (Spain), Brussels and Wallonia (Belgium), and Finland, respectively. This federated population-based observational study showed the effectiveness of the SARS-CoV-2 primary vaccination campaign in prolonging the mean time to infection in the Aragon (Spain) and Brussels and Wallonia (Belgium) population cohorts. Only a minor difference over this time frame was found in Finland\u2019s population cohort.<\/jats:p>","DOI":"10.1093\/eurpub\/ckaf247","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:51:27Z","timestamp":1765284687000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world comparative effectiveness of SARS-CoV-2 primary vaccination campaigns against SARS-CoV-2 infections: a federated observational study emulating a target trial in three nations"],"prefix":"10.1093","volume":"36","author":[{"given":"Marjan","family":"Meurisse","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Public Health, Sciensano , Brussels,","place":["Belgium"]},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique (IREC)\u2014EPID, Universit\u00e9 Catholique de Louvain , Brussels,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-8120","authenticated-orcid":false,"given":"Francisco","family":"Estupi\u00f1\u00e1n-Romero","sequence":"additional","affiliation":[{"name":"Data Science for Health Services and Policy, Instituto Aragon\u00e9s de Ciencias de la Salud (IACS) , Zaragoza,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-1667","authenticated-orcid":false,"given":"Markus","family":"Perola","sequence":"additional","affiliation":[{"name":"Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL) , Helsinki,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teemu","family":"Paajanen","sequence":"additional","affiliation":[{"name":"Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL) , Helsinki,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Gonz\u00e1lez-Galindo","sequence":"additional","affiliation":[{"name":"Data Science for Health Services and Policy, Instituto Aragon\u00e9s de Ciencias de la Salud (IACS) , Zaragoza,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Van Goethem","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, Sciensano , Brussels,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0961-3298","authenticated-orcid":false,"given":"Enrique","family":"Bernal-Delgado","sequence":"additional","affiliation":[{"name":"Data Science for Health Services and Policy, Instituto Aragon\u00e9s de Ciencias de la Salud (IACS) , Zaragoza,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2026040911300787300_ckaf247-B1","author":"EMA","year":"2021"},{"key":"2026040911300787300_ckaf247-B2","author":"European Centre for Disease Prevention and Control"},{"key":"2026040911300787300_ckaf247-B3","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","article-title":"Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom","volume":"27","author":"Pritchard","year":"2021","journal-title":"Nat Med"},{"key":"2026040911300787300_ckaf247-B4","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1016\/j.vaccine.2021.08.060","article-title":"Vaccine effectiveness against infection and onwards transmission of COVID-19: analysis of Belgian contact tracing data, January-June 2021","volume":"39","author":"Braeye","year":"2021","journal-title":"Vaccine"},{"key":"2026040911300787300_ckaf247-B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3201\/eid2803.212027","article-title":"Effectiveness of 3 COVID-19 vaccines in preventing SARS-CoV-2 infections, January\u2013May 2021, Aragon, Spain","volume":"28","author":"del Cura-Bilbao","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2026040911300787300_ckaf247-B6","doi-asserted-by":"crossref","first-page":"e0258704","DOI":"10.1371\/journal.pone.0258704","article-title":"Effectiveness of vaccination against SARS-CoV-2 infection and covid-19 hospitalisation among Finnish elderly and chronically ill\u2014an interim analysis of a nationwide cohort study","volume":"16","author":"Baum","year":"2021","journal-title":"PLoS One"},{"key":"2026040911300787300_ckaf247-B7","doi-asserted-by":"crossref","first-page":"2100420","DOI":"10.2807\/1560-7917.ES.2021.26.17.2100420","article-title":"Effectiveness of the Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021","volume":"26","author":"Fabiani","year":"2021","journal-title":"Eurosurveillance"},{"key":"2026040911300787300_ckaf247-B8","doi-asserted-by":"crossref","first-page":"2300670","DOI":"10.2807\/1560-7917.ES.2024.29.1.2300670","article-title":"Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged \u2265 65 years: results from a VEBIS network, Europe, October 2021 to July 2023","volume":"29","author":"Font\u00e1n-Vela","year":"2024","journal-title":"Eurosurveillance"},{"key":"2026040911300787300_ckaf247-B9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2026040911300787300_ckaf247-B10"},{"key":"2026040911300787300_ckaf247-B11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12874-023-02068-3","article-title":"Federated causal inference based on real-world observational data sources: application to a SARS-CoV-2 vaccine effectiveness assessment","volume":"23","author":"Meurisse","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"2026040911300787300_ckaf247-B12","unstructured":"Estupi\u00f1\u00e1n-Romero F, Van Goethem N, Meurisse M \u00a0et al \u00a0BY-COVID\u2014WP5\u2014Baseline Use Case: COVID-19 Vaccine Effectiveness Assessment\u2014Common Data Model Specification. 2022. 10.5281\/zenodo.6913046 (17 June 2024, date last accessed)."},{"key":"2026040911300787300_ckaf247-B13","author":"Meurisse"},{"key":"2026040911300787300_ckaf247-B14","author":"Meurisse","year":"2024"},{"key":"2026040911300787300_ckaf247-B15","unstructured":"Mart\u00ednez-Lizaga N, Meurisse M, Estupi\u00f1an-Romero F \u00a0et al \u00a0BY-COVID\u2014WP5\u2014Baseline Use Case: COVID-19 Vaccine Effectiveness Assessment\u2014Data Management Plan. 2023. 10.5281\/zenodo.7625783 (17 June 2024, date last accessed)."},{"key":"2026040911300787300_ckaf247-B16","unstructured":"Meurisse M, Van Goethem N, Estupi\u00f1\u00e1n-Romero F \u00a0et al \u00a0BY-COVID\u2014WP5\u2014Baseline Use Case: COVID-19 Vaccine Effectiveness Assessment\u2014Study Protocol. 2023. 10.5281\/zenodo.7560731 (17 June 2024, date last accessed)."},{"key":"2026040911300787300_ckaf247-B17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3348\/kjr.2022.0061","article-title":"Restricted mean survival time for survival analysis: a quick guide for clinical researchers","volume":"23","author":"Han","year":"2022","journal-title":"Korean J Radiol"},{"key":"2026040911300787300_ckaf247-B18","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"2026040911300787300_ckaf247-B19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026040911300787300_ckaf247-B20","unstructured":"Meurisse M, Estupi\u00f1\u00e1n-Romero F, Van Goethem N \u00a0et al \u00a0BY-COVID\u2014WP5\u2014Baseline Use Case: SARS-CoV-2 Vaccine Effectiveness Assessment\u2014Local Outputs and Comparative Analysis. 2024. 10.5281\/zenodo.11209362 (17 June 2024, date last accessed)."},{"key":"2026040911300787300_ckaf247-B21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.vaccine.2021.12.032","article-title":"Cohort study of covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021","volume":"40","author":"Poukka","year":"2022","journal-title":"Vaccine"},{"key":"2026040911300787300_ckaf247-B22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/jech-2023-220751","article-title":"Sociodemographic and socioeconomic disparities in COVID-19 vaccine uptake in Belgium: a nationwide record linkage study","volume":"78","author":"Cavillot","year":"2023","journal-title":"J Epidemiol Community Health"},{"key":"2026040911300787300_ckaf247-B23","doi-asserted-by":"crossref","first-page":"1605547","DOI":"10.3389\/ijph.2023.1605547","article-title":"Incidence of SARS-CoV-2 infection and factors associated with complete COVID-19 vaccine uptake among migrant origin persons in Finland","volume":"68","author":"Bastola","year":"2023","journal-title":"Int J Public Health"},{"key":"2026040911300787300_ckaf247-B24","doi-asserted-by":"crossref","first-page":"e1004038","DOI":"10.1371\/journal.pmed.1004038","article-title":"Income differences in COVID-19 incidence and severity in Finland among people with Foreign and native background: a population-based cohort study of individuals nested within households","volume":"19","author":"Saarinen","year":"2022","journal-title":"PLos Med"},{"key":"2026040911300787300_ckaf247-B25","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1186\/s12889-022-14774-6","article-title":"Socioeconomic differences in COVID-19 infection, hospitalisation and mortality in urban areas in a region in the South of Europe","volume":"22","author":"Fern\u00e1ndez-Mart\u00ednez","year":"2022","journal-title":"BMC Public Health"},{"key":"2026040911300787300_ckaf247-B26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13690-021-00704-2","article-title":"One year of laboratory based COVID-19 surveillance system in Belgium: main indicators and performance of the laboratories (march 2020-21)","volume":"79","author":"Meurisse","year":"2021","journal-title":"Arch Public Health"},{"key":"2026040911300787300_ckaf247-B27","author":"Ministry of Social Affairs and Health","year":"2021"},{"key":"2026040911300787300_ckaf247-B28","volume-title":"Strategy for COVID-19 Testing and Contact Tracing Updated to Prevent Spread of Disease Particularly among Risk Groups","author":"Ministry of Social Affairs and Health","year":"2022"},{"key":"2026040911300787300_ckaf247-B29","author":"COVID-19 Health System Response Monitor (HSRM","year":"2022"},{"key":"2026040911300787300_ckaf247-B30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(20)31483-5","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study","volume":"396","author":"Poll\u00e1n","year":"2020","journal-title":"Lancet"},{"key":"2026040911300787300_ckaf247-B31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/v14050920","article-title":"Prevalence of anti-SARS-CoV-2 antibodies and potential determinants among the Belgian adult population: baseline results of a prospective cohort study","volume":"14","author":"Leclercq","year":"2022","journal-title":"Viruses-Basel"},{"key":"2026040911300787300_ckaf247-B32","doi-asserted-by":"crossref","first-page":"2100419","DOI":"10.2807\/1560-7917.ES.2022.27.9.2100419","article-title":"Seroprevalence of IgG antibodies against SARS-CoV-2\u2014a serial prospective cross-sectional nationwide study of residual samples, Belgium, march to october 2020","volume":"27","author":"Herzog","year":"2022","journal-title":"Eurosurveillance"},{"key":"2026040911300787300_ckaf247-B33","doi-asserted-by":"crossref","first-page":"2222849","DOI":"10.1080\/22221751.2023.2222849","article-title":"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020\u20132022","volume":"12","author":"Solastie","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"2026040911300787300_ckaf247-B34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/irv.12993","article-title":"Vaccination status and testing rates in Finland\u2014a potential cause for bias in observational vaccine effectiveness analysis","volume":"16","author":"Kuitunen","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"key":"2026040911300787300_ckaf247-B35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/vaccines11010020","article-title":"Considerations in understanding vaccine effectiveness","volume":"11","author":"Lau","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2026040911300787300_ckaf247-B36","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.3390\/ijerph19127439","article-title":"Correlation between population density and COVID-19 cases during the third wave in Malaysia: effect of the Delta variant","volume":"19","author":"Md Iderus","year":"2022","journal-title":"IJERPH"},{"key":"2026040911300787300_ckaf247-B37","doi-asserted-by":"crossref","first-page":"e0242398","DOI":"10.1371\/journal.pone.0242398","article-title":"Spreading of COVID-19: density matters","volume":"15","author":"Wong","year":"2020","journal-title":"PLoS One"},{"key":"2026040911300787300_ckaf247-B38","first-page":"7","article-title":"Population density as a factor in the spread of covid-19 cases in peninsular Malaysia","volume":"17","author":"Abd Rasid","year":"2021","journal-title":"Malaya J Med Health Sci"},{"key":"2026040911300787300_ckaf247-B39","author":"Statistics | Eurostat"}],"container-title":["European Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurpub\/advance-article-pdf\/doi\/10.1093\/eurpub\/ckaf247\/66324980\/ckaf247.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurpub\/article-pdf\/36\/2\/ckaf247\/66324980\/ckaf247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurpub\/article-pdf\/36\/2\/ckaf247\/66324980\/ckaf247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:49:26Z","timestamp":1775749766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurpub\/article\/doi\/10.1093\/eurpub\/ckaf247\/8418146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurpub\/ckaf247","relation":{},"ISSN":["1101-1262","1464-360X"],"issn-type":[{"value":"1101-1262","type":"print"},{"value":"1464-360X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,1,7]]},"article-number":"ckaf247"}}